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Abstract
Most medical agents currently applied in osteoporosis therapy act by inhibiting bone resorption and reducing bone remodelling, i.e. they
inhibit the process of bone mass loss by suppressing bone resorption processes. These drugs provide an ideal therapeutic option to prevent
osteoporosis progression. They however have a rather limited usefulness when the disease has already reached its advanced stages with
distinctive bone architecture lesions. The fracture risk reduction rate, achieved in the course of anti-resorptive therapy, is insufficient for
patients with severe osteoporosis to stop the downward spiral of their quality of life (QoL) with a simultaneously increasing threat of
premature death.
The activity of the N-terminal fragment of 1–34 human parathormone (teriparatide — 1–34 rhPTH), a parathyroid hormone (PTH) ana-
logue obtained via genetic engineering , is expressed by increased bone metabolism, while promoting new bone tissue formation by
stimulating the activity of osteoblasts more than that of osteoclasts. The anabolic activity of PTH includes both its direct effect on the
osteoblast cell line, and its indirect actions exerted via its regulatory effects on selected growth factors, e.g. IGF-1 or sclerostin. However,
the molecular mechanisms responsible for the actual anabolic effects of PTH remain mostly still unclear.
Clinical studies have demonstrated that therapeutic protocols with the application of PTH analogues provide an effective protection
against all osteoporotic fracture types in post-menopausal women and in elderly men with advanced osteoporosis. Particular hopes are
pinned on the possibility of applying PTH in the therapy of post-steroid osteoporosis, mainly to suppress bone formation, the most
important pathological process in this regard.
The relatively short therapy period with a PTH analogue (24 months) should then be replaced and continued by anti-resorptive treatment.
(Pol J Endocrinol 2011; 62 (1): 73–78)
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Streszczenie
Większość leków stosowanych obecnie w terapii osteoporozy wykazuje działanie przeciwresorpcyjne, czyli spowalnia utratę masy kost-
nej poprzez hamowanie resorpcji kostnej. Stanowią one idealne leczenie w celu zapobiegania postępowi osteoporozy, wykazują jednak
ograniczoną przydatność, kiedy choroba jest zaawansowana, a architektura kości uszkodzona. Redukcja ryzyka złamań, uzyskiwana
w trakcie leczenia antyresorpcyjnego, jest niewystarczająca dla chorych z ciężką osteoporozą, aby powstrzymać postępujący spadek
jakości ich życia i rosnące zagrożenie przedwczesnym zgonem. Działanie otrzymywanego w technologii inżynierii genetycznej analogu
PTH, rekombinowanego N-końcowego fragmentu 1–34 ludzkiego parathormonu (teryparatydu — 1–34 rhPTH) wyraża się nasileniem
obrotu kostnego i promuje tworzenie nowej kości poprzez stymulowanie aktywności osteoblastów w większym stopniu niż aktywności
osteoklastów. Anaboliczne działanie PTH obejmuje zarówno bezpośredni wpływ na linię komórkową osteoblasta, jak szereg działań
pośrednich, poprzez regulacyjny wpływ PTH na wybrane czynniki wzrostowe, na przykład IGF-1 lub sklerostynę. Mechanizmy moleku-
larne odpowiadające za rzeczywisty efekt anaboliczny PTH pozostają jednak w większości nieznane.
Badania kliniczne wykazały, że leczenie analogami PTH skutecznie zapobiega wszystkim typom złamań osteoporotycznych u kobiet po
menopauzie i starszych mężczyzn z zaawansowaną osteoporozą. Szczególne nadzieje budzi możliwość zastosowania PTH w leczeniu
osteoporozy posteroidowej, ze względu na wiodące w tej patologii zahamowanie kościotworzenia. Względnie krótkotrwałe leczenie
analogiem PTH (24 miesiące) powinno być następnie kontynuowane leczeniem antyresorpcyjnym.
(Endokrynol Pol 2011; 62 (1): 73–78)
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Introduction
Fracture prevention is the number one target in os-
teoporosis therapy.
Most medical agents currently used for this purpose
include anti-resorptive drugs, which slow down bone
mass loss by suppressing bone resorption. This is the
mechanism of action of biphosphates, oestrogens, se-
lective oestrogen receptor modulators, calcitonin and
denosumab, i.e. the registered medical agents approved
for the treatment of osteoporosis [1]. Antiresorptive
drugs (taking into account the actual limitations in hor-
monal replacement therapy resulting from the studies
of the Women’s Health Initiative and the Million Wom-
en Study), are an ideal way of preventing osteoporosis
progression. However, they have limited usefulness in
more advanced stages of the disease, when the quality
of bone architecture is seriously compromised [2, 3].
In all the published, randomised, placebo-controlled
clinical studies, patients with osteoporosis who were
treated with antiresorptive agents sustained new bone
fractures significantly less frequently than placebo-ad-
ministered patients, although some new fractures oc-
curred in the actively treated group, though at a much
lower level. In the Fracture Intervention Trial (FIT), over
the course of a three-year observation, 8% of alendro-
nate-treated patients sustained a new vertebral fracture
(vs. 15% of placebo-receiving patients) [4, 5]. In the
three-year Multiple Outcomes of Raloxifene Evaluation
(MORE) study, new vertebral fractures were identified
in 14.7% of raloxifene-treated patients vs. 21.2% of pla-
cebo-receiving subjects [6]. Patients with severe osteo-
porosis and numerous fractures of vertebral bodies are
especially susceptible to subsequent osteoporotic frac-
tures, regardless of applied antiresorptive therapy. In
these patients, a 50% fracture risk reduction, obtained
during antiresorptive treatment, is insufficient to halt
the QoL (quality of life) drop that comes with the simu-
ltaneously growing risk of premature death [3].
An entirely new therapeutic strategy, based on
bone reconstruction factors (including PTH analogues
and strontium salts) would be a real breakthrough in
the management of patients with severe osteoporosis.
The ability of anabolic factors to improve bone min-
eral density much more efficiently than antiresorptive
agents would also suggest a higher fracture risk-reduc-
ing potential of the former substances [7–9].
Parathormone analogues
Endogenous parathyroid hormone (PTH) is secreted by
the four parathyroid glands, mainly as an 84-aminoac-
id peptide [PTH (1–84)] [10]. PTH secretion is controlled
by serum calcium concentration, by means of a nega-
tive feedback mechanism via the membrane calcium
receptor (CaR) [11]. In response to hypocalcaemia, PTH
acts directly to increase renal tubular calcium reabsorp-
tion and indirectly to enhance intestinal calcium absorp-
tion via its stimulatory action on renal 1-cholecalciferol
hydroxylase (thereby increasing circulating calcitriol).
The normal physiological role of PTH on skeletal ho-
meostasis, when secreted endogenously, is more com-
plex, but probably serves to regulate bone remodelling
rather than overall skeletal mass. Within the physiolog-
ical range of concentrations, PTH stimulates the bone-
forming activity of osteoblasts at the same level as the
bone-losing activity of osteoclasts [12].
But because normal concentrations and the pulsa-
tive character of PTH secretion support the bone for-
mation process, it is osteoclastic bone resorption, and
free osseous calcium ion release into the extracellular
fluid, which dominate in the situation of constantly ele-
vated PTH concentration, something characteristic of both
primary and secondary hyperparathyroidism (Fig. 1).
It is assumed that the primary biological activity of
endogenous PTH (1–84) depends on the N-terminal
fragment sequence, which is why the shortened, N-ter-
minal, 34-amino acid hPTH analogue (1–34) (teriparati-
de) preserves the features of the entire molecule [13].
The majority of PTH actions, as well as of the actions of
its evolutional analogue, a parathormone-related pep-
Figure 1. PTH activity: anabolic or catabolic, depending on
secretion rate and character
Rycina 1. Działanie PTH na tkankę kostną w zależności od
stężenia i sposobu wydzielania
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tide (PTHrP) [14], are mediated by PTH receptor type 1
(PTH-receptor-PTHrP), identifying and activated by the
above-mentioned N-terminal sequence of amino acids
[15]. The PTH receptor belongs to the class of membra-
nous receptors, characterised by a heptahelical protein
structure, associated with G protein and adenyl cycla-
se. The PTH receptor is localised in the bone on the os-
teoblast surface only. The primary, physiological activ-
ity of PTH, i.e. normocalcaemia control by enhancing
osteoclastic bone resorption and releasing the free cal-
cium ion into the extracellular space, is then an indirect
effect.
In pre-osteoblasts, PTH [16] amplifies the produc-
tion of RANKL (Receptor Activator of NFkappaB
Ligand) cytokine, belonging to the superfamily of tu-
mour necrosis factors (TNF), while simultaneously de-
creasing the release of osteoprotegerine, a soluble, de-
coy receptor for RANKL (OPG) [17-19]. It increases the
accessibility of RANKL for the functional RANK recep-
tor on the surface of the monocyte/macrophage-osteo-
blast development line cells [20]. In this way, RANKL
enhances the proliferation/differentiation/fusion/matu-
ration and metabolic activity of osteoclasts, so leading
to intensification of osteolysis.
Regarding osteoblasts, PTH simultaneously activates
cAMP-dependent protein kinase and calcium-depen-
dent C protein kinase, as well as MAP kinase and A and
D phospholipase, all of them of key importance for os-
teoblast activity [21]. The PTH-receptor complex also
undergoes internalisation and can thus exert significant
gene transcription controlling activity [22].
However, the specific signal pathway responsible
for the anabolic activity of PTH remains unknown, es-
pecially given that this particular activity is a combina-
tion of direct PTH effects on the cell line of osteoblasts
and of indirect action via the controlling influence of
PTH on selected bone growth factors and on the sub-
stances which are, for them, antagonistic. PTH demon-
strates mitogenic activity towards osteoblasts, inhibit-
ing their apoptosis [23]. In consequence, the number of
osteoblasts is growing. Independently from growth
hormone (GH) activity, PTH induces the synthesis of
the insulin-like growth factor 1 (IGF-1), a strong bone
anabolic factor, in bone tissue [21, 24–25]. At the same
time, PTH suppresses the expression of sclerostine, an
osteocyte-derived SOST protein, which blocks the ac-
tivity of the Wnt-beta-catenin pathway responsible for
promotion of many transcriptive processes, leading, in
effect, to the increased number and activity of osteo-
blasts [21, 26].
The mechanism of PTH anabolic activity also in-
cludes the transitional phase of bone surface prepara-
tion, together with bone matrix metaloproteinase syn-
thesis. Other PTH effects include modulation of locally
secreted paracrine factors (TGF-ß, transforming growth
factor beta), enzymes and other substances (including
prostaglandins), participating in cell replication process-
es and osteogenesis stimulation [27–30]. However, lit-
tle is known about the role of the type 2 receptor for
PTH [33], activated by the C-terminal section of PTH
(1–84), as well as by C-terminal fragments of PTH, ei-
ther directly released from the parathyroid glands or
produced as a result of peripheral degradation. It seems
that the C-terminal fragments of PTH enhance the apo-
ptosis of osteocytes [34], while when in cultures they
stimulate the synthesis of alkaline phosphatase and other
osteoblast activity markers [34]. So it is possible that the
therapeutic activity of the whole PTH molecule (1–84)
may slightly differ from teriparatide activity [36]. While
not dismissing the importance of that observation, it
should, however, be emphasised that the molecular
mechanism responsible for the actual anabolic effect of
PTH remains unknown. Similarly, it is not entirely clear
why an intermittent administration of small doses of
either exogenous PTH or teriparatide should exert main-
ly anabolic activity and differ in its final effect from an
exposure to long-term, elevated PTH concentrations
with a dominating catabolism of the cortex bone [31,
32]. It seems that a single administration of a short-act-
ing PTH preparation, or of its analogue, may imitate
a single, normal secretion pulse of the endogenous
hormone.
Clinical application
Teriparatide, the N-terminal 1–34 fragment of the hu-
man parathormone (rhPTH (1–34), teriparatide), ob-
tained via bioengineering and administered intermit-
tently , has turned out to be a factor promoting new
bone formation and bone weight increase much more
effectively than anti-resorptive agents. Studies on ani-
mals, and preliminary results of clinical studies, have
demonstrated that intermittent PTH treatment causes
a significant increase in cancellous bone weight, but ei-
ther does not influence the cortex core at all, or merely
diminishes it slightly [37, 38].
The effects of teriparatide therapy on the risk of os-
teoporotic, vertebral and non-vertebral fractures in post-
menopausal women were evaluated in the Fracture
Prevention Trial, a clinical trial involving 1,637 post-
menopausal women with confirmed osteoporosis [39].
After 18 months of therapy with daily subcutaneous
teriparatide injections in 20 mg doses, a significant re-
duction in both new fractures (vertebral by 65% and
non-vertebral by 54% vs. placebo) was demonstrated.
Moreover, the treatment with teriparatide resulted in
significant, dose-dependent bone mineral density
(BMD) increase in the lumbar spine, the hip and the
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whole skeleton vs. the control group (p < 0.001 for all
the values). As with the antiresorptive agents, the ob-
served reduction in fracture risk may only partly be
explained by the BMD increase. A certain reduction in
the vertebral fracture risk was also observed in post-
menopausal women treated with recombined PTH
(1–84). However, the high percentage of patients who
did not complete the study was a serious obstacle to
the statistical evaluation of the observations [40].
A favourable effect of treatment with PTH analogues
on BMD has also been demonstrated in men with ad-
vanced osteoporosis. In a short-term observation of
437 men with low BMD values, an administration of recom-
bined human PTH (1–34) (teriparatide, 20–40 mg sc/d)
for 2–15 months resulted in significant BMD increase in
the lumbar spine and in the hip (though not in the radial
bone or in the total body) and increased bone turnover.
In that study, the therapy effects on fracture risk were
not evaluated; but the similarity of those effects on BMD
and BTM with the effects observed in clinical studies of
women where the influence of the treatment on fracture
incidence was assessed, clearly indicates the therapeutic
usefulness of teriparatide in both sexes [41].
Histomorphometric studies of biopsied bone mate-
rial, collected from teriparatide-treated subjects, have
revealed not only increased bone trabecular volumes
but also higher numbers of trabeculas and of intertra-
becular connections, as well as improved cancellous
bone architecture and increased cortical bone thickness
[42, 43].
Moreover, it seems that PTH better stimulates os-
teogenesis on subperiosteal bone surface, which increas-
es periosteal apposition [44]. It brings about favourable
changes for bone geometry by increasing its dimensions,
which, in consequence, leads to improved bone resis-
tance to mechanical stress [45].
The study, initially scheduled for three years, was
prematurely stopped (on average after 19 months of
therapy). The cause of the early termination was os-
teosarcoma development in rats that had been admin-
istered supraphysiological doses of teriparatide for al-
most their whole lives [46, 47]. No development of any
neoplastic bone changes was observed in other animal
species (monkeys included), treated in the same way
[48]. A single case of osteosarcoma described in a wom-
an treated with teriparatide for almost a year vs. around
800,000 teriparatide-treated subjects, has to be interpret-
ed as corresponding to the population risk of occurrence
of this extremely rare neoplasm [49]. However, regard-
ing the oncological concerns, the administration time
period of PTH analogues has been reduced to 24 months
(FDA, EMEA). Any oncological episode in the past, or
Paget’s disease, or previous skeleton irradiation, is an
absolute contraindication to the administration of PTH
analogues; these agents are also contraindicated in chil-
dren.
A possibility to apply PTH analogues in the therapy
of glucocorticosteroid-induced osteoporosis (GIO) raises
particular hopes for osteogenesis suppression, a lead-
ing disorder in this pathology [50]. In a clinical study,
comparing head-to-head teriparatide with alendronate
in women and men with GIO, a significantly higher
increase in BMD, with a lower incidence of vertebral
fractures, was noted in the group of patients adminis-
tered PTH (1–34) for 18 months [51].
A relatively brief anabolic therapy (24 months) with
PTH analogues raises an obvious question, namely what
to do after the therapy. The results of observations made
in the course of large clinical studies indicate a consid-
erable bone mass loss after teriparatide treatment, both
in women and men, unless antiresorptive agents are
not immediately applied [52]. Also in a clinical study of
treating post-menopausal osteoporosis with rhPTH
(1–84), the favourable effects of therapy continuation
were observed, with alendronate administered imme-
diately after PTH withdrawal [53, 54].
Conclusions from the available data should be drawn
with great caution, if at all, because of the lack of pro-
spective studies, the rather small study population, and,
especially, the lack of evaluation of the antiresorptive
treatment, applied after the termination of PTH ana-
logue therapy, on the incidence of fractures. It seems,
however, that antiresorptive treatment preventing bone
mass loss after teriparatide withdrawal should be rec-
ommended [55].
The necessity for daily subcutaneous injections of
PTH analogues significantly diminished patients’ accep-
tance of this therapy. An alternative may soon be pro-
vided by a novel teriparatide transdermal microneedle
delivery system. This comprises a 5 cm2 adhesive patch
with TPTD coated on a 2 cm2 titanium microneedle ar-
ray with 1,300 microneedles of a 190 µm average length.
The tips of the microneedles are coated with teriparati-
de. The recently published results of a clinical, phase-
two study demonstrated not only a comparable effect
(non-inferiority) of subcutaneously injected teriparati-
de on vertebral BMD and on the activity of bone me-
tabolism markers, but also a higher BMD increase in
the proximal femoral bone (superiority) in transcuta-
neously treated patients [56].
The introduction of PTH analogues to osteoporo-
sis therapy seems to be particularly advantageous for
patients at advanced stages of the disease, with high
fracture risk. Teriparatide is now the only medical agent
reconstructing bone tissue structure, regardless of the
degree of its initial destruction.
On the other hand, the relative decrease of fracture
incidence obtained in patients treated with teriparati-
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tion after modern anti-resorptive drugs.
Several questions arise, such as:
— would therapy split into shorter cycles (intermittent
treatment) give a better therapeutic effect?
— would therapy longer than 18–24 months provide
a more efficient outcome?
— would there be more positive results if the therapy was
repeated after a certain time period (cyclic treatment)?
We do not have answers to these and other ques-
tions.
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